As­traZeneca’s Tagris­so hits the mark in late-stage lung can­cer main­te­nance study

As­traZeneca’s Tagris­so has im­proved sur­vival out­comes in a Phase III main­te­nance test for cer­tain lung can­cer pa­tients, paving the way for the drug to ex­pand its mar­ket by at least $500 mil­lion, ac­cord­ing to the com­pa­ny.

The LAU­RA tri­al en­rolled 216 sub­jects with un­re­sectable stage 3 epi­der­mal growth fac­tor re­cep­tor (EGFR) mu­tat­ed non-small cell lung can­cer whose dis­ease had not pro­gressed af­ter plat­inum-based chemora­dio­ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.